Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

  • This share is currently suspended. It was suspended at a price of 0.01
  • There is currently no data for VRS

Trading Update

6 Apr 2016 07:00

RNS Number : 2797U
Versarien PLC
06 April 2016
ย 

ย 

6 April 2016

Versarien plc("Versarien" or the "Company")

ย 

Trading Update

ย 

Versarien Plc (AIM: VRS), the advanced materials engineering group is pleased to give the following update on trading and corporate activity for the financial year ended 31 March 2016.

ย 

The Company is pleased to report that it expects revenue and loss before income tax (after exceptional charges and share based payment charges) for the year ended 31 March 2016 to be broadly in line with market forecasts. The full audited results for the year ended 31 March 2016 are expected to be announced on 19 July 2016.

ย 

Versarien continues to make significant progress with its two core technologies, graphene and copper foam thermal solutions, and whilst trading in the Company's profitable Hard Wear Products division remains constrained, primarily due to continuing low capex in the oil and gas sector, progress is being made with customers in other sectors.

ย 

The Company is particularly pleased with the high levels of enquiries being received for its low profile thermal copper heat dissipation solutions from multinational blue chip companies looking to incorporate Versarien's technology in high volume applications.

ย 

New graphene applications continue to be developed through a number of collaborations, particularly in the areas of composites and batteries. Versarien's ability to supply high quality graphene in commercial quantities following the breakthrough in the scalable manufacture of graphene platelets, announced last year, is driving considerable interest in incorporating graphene into a wide variety of real world applications.

ย 

Acquisitive Strategy

ย 

As indicated at the time of the interim results in December 2015, Versarien continues to look for appropriate acquisitions, particularly for graphene applications. The Company is pleased to announce that it has recently signed heads of terms to acquire two companies where graphene inclusion would provide significant product and market benefits, funding of which is expected to be largely supported by existing cash resources and bank debt. Further details will be announced as and when these transactions progress.

ย 

Neill Ricketts, CEO of Versarien plc commented: "We are pleased with the performance of the Company in the financial year just ended. Going forward we are seeing increasing demand for both our graphene and copper foam heat dissipation technologies and we look forward to bringing these cutting edge products to the market.

ย 

The Board continues to view the future with confidence and is delighted with the progress made in its core disruptive technologies to date."

ย 

For further information please contact:

ย 

Versarien plc

www.versarien.com

Neill Ricketts - Chief Executive Officer

+44 (0) 1594 888 622

Chris Leigh - Chief Financial Officer

WH Ireland (Nominated Adviser and Broker)

www.wh-ireland.co.uk

John Wakefield / Ed Allsopp

+44 (0) 117 945 3470

IFC Advisory (Financial PR and IR)

www.investor-focus.co.uk

Tim Metcalfe / Graham Herring / Heather Armstrong

+44 (0) 20 3053 8671

ย 

ย 

ย 

This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
TSTFMGGDNKRGVZM
Date   Source Headline
9th Feb 20267:00 amRNSCancellation - Versarien Plc
6th Jan 20261:34 pmRNSAppointment of Administrators
19th Dec 20254:36 pmRNSUpdate on NOIA
19th Dec 20254:36 pmRNSUpdate on NOIA
15th Dec 20253:53 pmRNSUpdate on the Disposal of AAC Cyroma Limited
12th Dec 20257:00 amRNSUpdate on NOIA and Change of Registered Office
1st Dec 20257:30 amRNSSuspension - Versarien plc
1st Dec 20257:00 amRNSIntention to Appoint Administrators, Suspension
26th Nov 20257:00 amRNSUpdate - Proposed Disposal of the Company's Assets
31st Oct 20258:48 amRNSProposed Disposal of the Company’s Assets
29th Sep 20252:32 pmRNSCorporate Update
10th Sep 20251:00 pmRNSCorporate Update
29th Aug 20252:19 pmRNSCorporate Update
21st Aug 20257:00 amRNSStrategic Investment and Joint Venture Update
11th Aug 20257:00 amRNSCorporate Update
5th Aug 202511:03 amRNSHolding(s) in Company
29th Jul 20257:00 amRNSCorporate Update
22nd Jul 202510:55 amRNSSettlement of Legal Claims
4th Jul 20257:00 amRNS-RSouth American Polygrene™ Themoplastics Agreements
30th Jun 20253:03 pmRNSInterim Results
19th Jun 20252:34 pmRNSBuilding for Humanity – Contract Update
4th Jun 202511:49 amRNSHolding(s) in Company
2nd Jun 20252:03 pmRNSHolding(s) in Company
30th May 202510:19 amRNSHolding(s) in Company
30th May 20257:00 amRNSTotal Voting Rights
29th May 20253:29 pmRNSHolding(s) in Company
29th May 202510:20 amRNSHolding(s) in Company
27th May 202511:59 amRNSHolding(s) in Company
27th May 202511:02 amRNSHolding(s) in Company
23rd May 20259:38 amRNSHolding(s) in Company
22nd May 202511:56 amRNSHolding(s) in Company
21st May 202510:58 amRNSHolding(s) in Company
20th May 202511:11 amRNSHolding(s) in Company
14th May 20257:00 amRNSPlacing to raise £425,000
2nd May 202511:00 amRNSUpdate on Legal Claims
28th Apr 20251:04 pmRNSResult of AGM
27th Mar 20257:00 amRNSAudited Results for year ended 30 September 2024
24th Mar 202511:24 amRNSResult of General Meeting
10th Mar 20257:00 amRNS-RGraphinks™ supply agreement with Montana Química
5th Mar 20257:00 amRNSNotice of General Meeting
3rd Mar 20257:00 amRNSCompletion of Sale of Korean Assets
28th Feb 20257:00 amRNSTotal Voting Rights
27th Feb 20257:00 amRNSInnovate UK Loan Deed of Variation
10th Feb 20258:35 amRNSHolding(s) in Company
28th Jan 20252:36 pmRNSPlacing to raise £246k
30th Dec 202412:00 pmRNSUpdate on Sale of Korean Assets
13th Dec 20242:58 pmRNSHolding(s) in Company
13th Dec 202411:50 amRNSHolding(s) in Company
13th Dec 202410:11 amRNSHolding(s) in Company
13th Dec 20247:00 amRNS€804,000 Grant Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.